Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II pediatric dose-finding study of racemic and levo-praziquantel orally dispersible tablets
PACTR201604001493593Phase 2Unknown
- Sponsor
- Merck KGaA
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of praziquantel and levopraziquantel in schistosomiasis, intestinal schistosomiasis and schistosomiasis haematobium (3 arms), sponsored by Merck KGaA. Primary endpoint: Clinical cure. Status: unknown.
02
Drugs
praziquantellevopraziquantel
03
Conditions
schistosomiasisintestinal schistosomiasisschistosomiasis haematobium
Beyond the preview
Go deeper on PACTR201604001493593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201604001493593.